Zobrazeno 1 - 10
of 28
pro vyhledávání: '"N. Navas-Iglesias"'
Autor:
C. González-López, S. Sandoval Fernández del Castillo, M. Camean-Fernández, N. Navas-Iglesias, D. Fernández-Prieto, M.Á. Calleja-Hernández, L.J. Roca-Ruiz, A. Gutiérrez-Pizarraya, J.J. Ballester-Alfaro, María Núñez-Núñez, J. García-Donaire, M Murillo-Izquierdo, M.M. Villanova-López, A. Pérez-Pérez
Publikováno v:
Revista Española de Cirugía Ortopédica y Traumatología. 64:134-142
Resumen Objetivos Comparar la eficacia y seguridad de la infiltracion de plasma rico en plaquetas preparado respecto a acido hialuronico en pacientes con coxartrosis refractaria a tratamiento conservador. Asi como correlacionar el impacto clinico ent
Autor:
A. Gutiérrez-Pizarraya, J. García-Donaire, M Murillo-Izquierdo, N. Navas-Iglesias, A. Pérez-Pérez, S. Sandoval Fernández del Castillo, C. González-López, L.J. Roca-Ruiz, M.Á. Calleja-Hernández, D. Fernández-Prieto, J.J. Ballester-Alfaro, M.M. Villanova-López, María Núñez-Núñez, M. Camean-Fernández
Publikováno v:
Revista Española de Cirugía Ortopédica y Traumatología (English Edition). 64:134-142
Aims of the study To compare the efficiency and safety of platelet-rich plasma (PRP) injection versus hyaluronic acid (HA) in patients with hip osteoarthritis (OA) not responding to symptomatic treatment, and to correlate cellular composition of PRP
Autor:
M M, Villanova-López, M, Núñez-Núñez, D, Fernández-Prieto, C, González-López, J, García-Donaire, A, Pérez-Pérez, S, Sandoval Fernández Del Castillo, M, Murillo-Izquierdo, M, Camean-Fernández, A, Gutiérrez-Pizarraya, N, Navas-Iglesias, L J, Roca-Ruiz, M Á, Calleja-Hernández, J J, Ballester-Alfaro
Publikováno v:
Revista espanola de cirugia ortopedica y traumatologia (English ed.). 64(2)
To compare efficacy and safety of a home-made platelet-rich plasma (PRP) solution versus hyaluronic acid in patients with hip osteoarthritis not responding to conservative treatment and to correlate cellular composition of PRP to clinical outcomes.Th
Publikováno v:
Drug information and pharmacotherapy.
Background The Inflectra (infliximab) product monograph indicates slightly higher aggregate proportions than the reference product Remicade. Purpose To evaluate the similarity between the reference Remicade and its marketed biosimilar Inflectra by me
Publikováno v:
Talanta. 43:1457-1463
A method for the simultaneous determination of quinoline yellow (QY) and brilliant blue FCF (BB) in mixtures by solid-phase spectrophotometry has been developed. Both colorants were isolated in Sephadex DEAE A-25 gel showing maximum absorbances at 63
Autor:
J Hernández Jiménez, N Navas Iglesias, A Salmerón García, I Suárez González, A Martínez Ortega, J Cabeza Barrera
Publikováno v:
European Journal of Hospital Pharmacy. 22:A127.2-A127
Background Cetuximab (CTX) (Erbitux) is a chimeric mouse-human monoclonal antibody IgG1 targeting epidermal growth factor receptor (EGFR). It is approved for use as treatment for metastatic colorectal cancer and squamous cell carcinoma of the head an
Autor:
A Salmerón García, I Suárez González, J Cabeza Barrera, N Navas Iglesias, L.F. Capitán Vallvey
Publikováno v:
European Journal of Hospital Pharmacy. 22:A125.2-A125
Background Cetuximab (CTX) (Erbitux) is a chimeric mouse-human monoclonal antibody IgG1 targeting epidermal growth factor receptor (EGFR). It is approved for use as treatment for metastatic colorectal cancer and squamous cell carcinoma of the head an
Autor:
I Suárez González, A Salmerón García, J Cabeza Barrera, L.F. Capitán Vallvey, N Navas Iglesias
Publikováno v:
European Journal of Hospital Pharmacy. 22:A127.1-A127
Background Trastuzumab (TRZ) (Herceptin) is a humanised monoclonal antibody IgG1 that acts against human epidermal growth factor receptor 2 (HER2). It is indicated in the treatment of early and metastatic breast cancer and metastatic gastric cancer.
Autor:
J Hernández Jiménez, J Cabeza Barrera, A Salmerón García, I Suárez González, N Navas Iglesias, A Martínez Ortega
Publikováno v:
European Journal of Hospital Pharmacy. 22:A127.3-A128
Background The use of an alternative liquid anaesthetic sevoflurane has recently been reported in the literature on vascular ulcers. Topical application for management of analgesia appears to be successful. Purpose To evaluate the stability of sevofl
PP-017 Evaluation of long-term biological activity of bevacizumab 25 mg/ml by an AD HOC elisa method
Autor:
N Navas Iglesias, L.F. Capitán Vallvey, I Suárez González, J Cabeza Barrera, A Salmerón García
Publikováno v:
European Journal of Hospital Pharmacy. 22:A123.2-A123
Background Bevacizumab (BVZ), the active substance of Avastin (25 mg/mL BVZ), is a humanised anti-vascular endothelial growth factor (VEGF) monoclonal antibody indicated in the treatment of several cancers. Purpose To evaluate the biological activity